IBONYSEPharmaceutical PreparationsFiscal year ends December 31
IMPACT BIOMEDICAL INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026
$3.06+0.38 (+14.18%)
Close on Oct 19, 2026
- Market cap
- $329.93M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
+$2.46 (+413.3%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.
IMPACT BIOMEDICAL INC. reported revenue of $35.00K for the twelve months to Jun 30, 2026.
Revenue
$35.00K
TTM Q2 2026
Operating income
-$5.11M
TTM Q2 2026
EPS, diluted
-$0.38
FY2025
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $329.93M
- P/E ratio
- –
- Price to sales
- 9426.66
- Price to book
- 30.65
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- $35.00K
- Net income
- $789.00K
- EPS, diluted
- -$0.38
- Book value per share
- $0.10
- Diluted shares
- 108M
Four years at a glance
Fiscal years 2022 to 2025 and trailing twelve months, USD
Revenue
$35.00K
Gross profit
–
Operating income
-$5.11M
Net income
$789.00K
EPS, diluted
–
Reported periodTrailing twelve months